We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Panel Gives Thumbs Down to Leqembi for Early Alzheimer’s
EMA Panel Gives Thumbs Down to Leqembi for Early Alzheimer’s
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has declined to recommend approval of Eisai’s Leqembi (lecanemab) for treatment of early Alzheimer’s disease, citing concerns over the drug’s safety.